Clinical trial · Observational
Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting
Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia (CML-CP) in a Community Oncology Setting
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This was a retrospective observational study to examine treatment patterns, molecular testing patterns, treatment response, and clinical outcomes among patients initiating first-line (1L) tyrosine kinase inhibitor (TKI) treatment for CML-CP in The United States (US) Oncology Network practices. Patients who initiated 1L therapy between 01 January 2016 and 31 December 2022 were eligible for inclusion in the study. Study-eligible patients were followed longitudinally post-index until death (if the patient had documentation of death during the study observation period) or last available patient record that occurred on or before the end of the study observation period. The study observation period was from 01 January 2016 to 30 November 2023. The index date was defined as the start date of 1L therapy for CML-CP.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Myeloid, Chronic-Phase | Leukemia | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- CML-CP Group
- description
- Patients with a diagnosis of CML-CP who initiated 1L TKI treatment in The US Oncology Network practices between 01 January 2016 and 31 December 2022.
Primary outcomes (28)
- measure
- Time From Initial CML Diagnosis to Initiation of 1L TKI Treatment
- timeFrame
- Baseline
- measure
- Number of Patients who Received a Stem Cell Transplant (SCT)
- timeFrame
- Up to approximately 7 years
- measure
- Number of Patients by Type of 1L and Second-line (2L) TKI Treatment
- timeFrame
- Up to approximately 7 years
- measure
- Number of Patients by Initial Dose of Each TKI in 1L and 2L Treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: 1. Patients whose data were accessible for research purposes during the study observation period. 2. Patients diagnosed with CML-CP at first recorded diagnosis of CML. 3. Patients ≥ 18 years of age at first recorded diagnosis of CML. 4. Patients who initiated qualifying 1L therapy for CML-CP during the study identification period. Qualifying 1L therapy treatments consisted of imatinib, dasatinib, bosutinib, or nilotinib as monotherapy. 5. Patients with ≥1 visit within The US Oncology Network practices following initiation of 1L therapy and through the end of the study observation period. Exclusion criteria: 1. Patients enrolled in interventional clinical trials during the study observation period. 2. Patients who received any systemic treatment indicated for another primary cancer during the study observation period.
References
Publications (0)
Data not yet available